Kamangar F, Dores GM, Anderson WF: Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. J Clin Oncol. 2006, 24 (14): 2137-2150. 10.1200/JCO.2005.05.2308.
Article
PubMed
Google Scholar
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ: Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med. 2006, 355 (1): 11-20. 10.1056/NEJMoa055531.
Article
CAS
PubMed
Google Scholar
Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA: Response to Neoadjuvant Chemotherapy Best Predicts Survival After Curative Resection of Gastric Cancer. Annals of Surgery. 1999, 229 (3): 303-308. 10.1097/00000658-199903000-00001.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006, 24 (24): 3953-3958. 10.1200/JCO.2006.06.4840.
Article
CAS
PubMed
Google Scholar
Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K: Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study. Clinical Cancer Research. 2008, 14 (7): 2012-2018. 10.1158/1078-0432.CCR-07-0934.
Article
CAS
PubMed
Google Scholar
Javle M, Hsueh CT: Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol. 2010, 3: 11-10.1186/1756-8722-3-11.
Article
PubMed Central
PubMed
Google Scholar
Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985, 230 (4730): 1132-1139. 10.1126/science.2999974.
Article
CAS
PubMed
Google Scholar
Park D, Yun J, Park J, Oh S, Kim H, Cho Y, Sohn C, Jeon W, Kim B, Yoo C: HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Digestive Diseases and Sciences. 2006, 51 (8): 1371-1379. 10.1007/s10620-005-9057-1.
Article
CAS
PubMed
Google Scholar
Kim SY, Kim HP, Kim YJ, Oh do Y, Im SA, Lee D, Jong HS, Kim TY, Bang YJ: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008, 32 (1): 89-95.
PubMed
Google Scholar
Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005, 16 (2): 273-278. 10.1093/annonc/mdi064.
Article
CAS
PubMed
Google Scholar
Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemotherapy and Pharmacology. 2007, 59 (6): 795-805. 10.1007/s00280-006-0337-z.
Article
CAS
PubMed
Google Scholar
Cortes-Funes H, Rivera F, Ales I, Marquez A, Velasco A, Colomer R, Garcia-Carbonero R, Sastre J, Guerra J, Gravalos C: Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J Clin Oncol (Meeting Abstracts). 2007, 25 (18_suppl): 4613--
Google Scholar
Gravalos C, Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008, 19 (9): 1523-1529. 10.1093/annonc/mdn169.
Article
CAS
PubMed
Google Scholar
Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol (Meeting Abstracts). 2009, 27 (15S): LBA4509--
Google Scholar
Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Rueschoff J, Van Cutsem E: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol (Meeting Abstracts). 2009, 27 (15S): 4556--
Google Scholar
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med. 2008, 358 (1): 36-46. 10.1056/NEJMoa073149.
Article
CAS
PubMed
Google Scholar
Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005, 10 (Suppl 3): 49-58. 10.1634/theoncologist.10-90003-49.
Article
CAS
PubMed
Google Scholar
Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006, 24 (31): 4991-4997. 10.1200/JCO.2006.06.8429.
Article
CAS
PubMed
Google Scholar
Andersen M, Schonnemann KR, Yilmaz M, Jensen HA, Vestermark LW, Pfeiffer P: Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Acta Oncol. 2010,
Google Scholar
Moehler MH, Thuss-Patience P, Arnold D, Grothe W, Stein A, Seufferlein T, Mantovani Loeffler L, Geissler M, Hofheinz RD, Schmoll H: Docetaxel, oxaliplatin, and capecitabine (TEX regimen) for patients with metastatic gastric cancer: Interim results from a phase II trial by the German AIO Group. J Clin Oncol (Meeting Abstracts). 2009, 27 (15S): 4554--
Google Scholar
Chien KR: Herceptin and the Heart -- A Molecular Modifier of Cardiac Failure. N Engl J Med. 2006, 354 (8): 789-790. 10.1056/NEJMp058315.
Article
CAS
PubMed
Google Scholar